Results Earnings Call for Q2FY23 of Syngene International
Conference Call with Syngene International Management and Analysts on Q2FY23 Performance and Outlook. Listen to the full earnings transcript.20-10-2022
20-10-2022
Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated October 19, 2022, regarding outcome of the Board Meeting and financials for the quarter and half year ended September 30, 2022, please find enclosed herewith the copy of newspaper publication of the financials in Financial Express (All India Edition) and Vijayavani (Bengaluru Edition) published on October 20, 2022.20-10-2022
Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Intimation of audio recording for Q2 FY23 post earnings call.20-10-2022
Syngene: Can it keep its premium valuation, going forward?
Investment in biologics is expected to remain recurring as new opportunities are unfolding in the field of biologics for Syngene20-10-2022
Q2FY23 Quarterly Result Announced for Syngene International Ltd.
Pharmaceutical company Syngene International announced Q2FY23 results: Syngene reports second quarter results from revenue from operations up 26% to Rs. 768 crores PAT increased 11% to Rs. 102 crore Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited, said, "The quarter saw positive performances across all divisions. Our research divisions: Discovery Services, including Synvent, our integrated drug discovery platform, and the Dedicated Centres showed sustained growth. Discovery Chemistry in particular saw buoyant customer demand. Growth in Development Services was led by existing clients renewing contracts and setting up collaborations on additional projects. The highlight in Manufacturing Services was the successful completion of the process performance qualification batches at a commercial scale for Zoetis. We are on track for the next important regulatory audits which will pave the way for the commercial manufacturing of the drug substance for Librela®*, a Zoetis product, from the fourth quarter of FY23. With a strong first half of the year behind us we are on track to achieve our guidance, including the upgraded revenue growth target announced in July.” Result PDF19-10-2022
Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter ended September 30, 2022. The Company will use this presentation for any meeting scheduled with analysts or institutional investors up to December 31, 2022.19-10-2022
Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled 'Syngene reports second quarter results Revenue from operations up 26% to Rs. 768 crores, PAT increased 11% to Rs. 102 crores'19-10-2022
Syngene International Ltd - 539268 - Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2022.
Unaudited Financial Results for the quarter and half year ended September 30, 2022.19-10-2022
Syngene International Ltd - 539268 - Board Meeting Outcome for Outcome Of The Board Meeting - October 19, 2022.
Outcome of the Board Meeting - October 19, 2022.19-10-2022
Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the intimation for conference call for Analysts and Investors to be held on Thursday, October 20, 202214-10-2022